CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...